UK-funded study to investigate patients’ experience of cell and gene therapies
Innovate UK is helping to fund the PROmics study, a programme designed to assess the effect of cell therapies on patient symptoms and quality of life.
Archives for December 5, 2018
Partnership will expand research into ‘urgently needed’ area
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
ARG acquires UK-based CRO in first move outside the US
ARG has made the move across the Atlantic, establishing its first office outside of the US following its acquisition of the UK-based CRO CCA Clinical Research.
How the industry is addressing the ethical concerns of incorporating big data into health care
In the era of big data, the industry is working to address the ethical concerns of integrating patient information into the health care landscape – though a key challenge will be reaching a consensus on what constitutes reliable evidence.
Shouldering the responsibility: Male birth control absorbed through skin
A clinical trial has begun to test the safety and efficacy of male birth control in a drug delivered through application on the arms and shoulders.
Guest column
To access the rewards of big data in health care, potential risks must be managed
Increased access to real-world data sources opens up new possibilities, but it also raises new ethical questions, which cannot be tackled by one organization, government agency, or company alone.
Voyager taps Brammer and Fujifilm for gene therapy development program
The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.
Mylan expands valsartan recall in US
Mylan has requested all lots of valsartan, as well as combination amlodipine/valsartan, and valsartan/ hydrochlorothiazide tablets, be returned in the US.
US inspection protocols offer a more transparent, risk-based approach, says Recipharm
The US FDA’s New Inspection Protocol Project represents an “improvement process step” towards a risk-based site selection model, according to the Swedish CDMO.